1. Introduction {#sec1-ijerph-13-00458}
===============

Cardiovascular disease (CVD), including essential hypertension (EH), is the leading cause of mortality throughout the world \[[@B1-ijerph-13-00458]\]. Among the important worldwide public-health challenges, hypertension has become an independent predisposing factor for many cardiovascular diseases, including coronary heart disease, heart failure stroke and many other serious cardiovascular diseases. It is estimated that hypertension is the third most important risk factor for disability-adjusted life-years \[[@B2-ijerph-13-00458],[@B3-ijerph-13-00458]\]. Although mortality caused by cardiovascular disease has recently declined, the burden of CVD remains high \[[@B4-ijerph-13-00458]\]. Hypertension is a complex disease regulated by many interactional systems that have remained unclear until now \[[@B5-ijerph-13-00458]\]. Hypertension is likely to be a type of multifactorial, polygenic and genetic disorder influenced by genetic variations \[[@B5-ijerph-13-00458],[@B6-ijerph-13-00458]\], and there are some reports on possible candidate genes \[[@B7-ijerph-13-00458]\]. Genetic elements played a vital role in the range of blood pressure \[[@B8-ijerph-13-00458]\] in human essential hypertension; blood ANP levels are considered to be higher than those in normal subjects \[[@B9-ijerph-13-00458]\]. In recent years, many studies have discussed the relationships between genetic polymorphisms and essential hypertension, but some of the conclusions are inconsistent and unconvincing.

Atrial natriuretic peptide (ANP), which is also called atrial natriuretic factor (ANF), is a cardiac hormone that is synthesized and secreted in cardiac atrial \[[@B9-ijerph-13-00458],[@B10-ijerph-13-00458],[@B11-ijerph-13-00458]\]. The main physiological role of ANP is to make vascular smooth muscle diastolic and induce apoptosis in cultured cardiac myocytes; in addition, ANP can inhibit rennin-angiotensin-aldosterone and myocardial contractile activity \[[@B12-ijerph-13-00458],[@B13-ijerph-13-00458]\]. ANP plays an important role in the regulation of blood pressure \[[@B14-ijerph-13-00458]\]. In order to provide evidence for the prevention of essential hypertension, many researchers have conducted a series of studies exploring the potential relationships between atrial natriuretic peptide (ANP) genetic polymorphism and essential hypertension \[[@B7-ijerph-13-00458],[@B15-ijerph-13-00458],[@B16-ijerph-13-00458]\]. According to existing studies, several candidate genes have been identified as risk factors of EH; the human ANP gene may be a possible candidate gene contributing to the risk of EH or other cardiovascular diseases \[[@B17-ijerph-13-00458],[@B18-ijerph-13-00458]\]. Consequently, the current meta-analysis was conducted to examine whether the ANP polymorphisms are associated with patients with essential hypertension.

2. Materials and Methods {#sec2-ijerph-13-00458}
========================

2.1. Literature Search Strategy {#sec2dot1-ijerph-13-00458}
-------------------------------

We systematically searched PubMed, the Cochrane Library, Wiley, Embase, China National Knowledge Infrastructure (CNKI), and the Chinese WanFang Database for reports of populations based on case-control or cohort design studies published before 1 December 2015. The databases were searched by two authors independently using the following keywords: ("essential hypertension" or "primary hypertension" or "hypertension" or "blood pressure" or "arterial pressure") AND ("atrial natriuretic factor" or ''ANF'' or ''atrial natriuretic peptide'' or ''ANP'' or ''atrial natriuretic hormone'' or "ANH" or ''natriuretic peptides'' or "NPPA" or" natriuretic peptide precursor A") AND (''mutation'' or ''polymorphism, genetic'' or ''variation'' or ''polymorphism'' ''polymorphism, single nucleotide" or ''single nucleotide polymorphism'' or ''SNP'' or ''variant'' or "alleles" or "allele" or "genotype"). We also performed a manual search of the reference lists from relevant articles to find other potential articles. The search was conducted on studies published in English and Chinese.

2.2. Inclusion Criteria {#sec2dot2-ijerph-13-00458}
-----------------------

Studies that met the following criteria were included: (1)studies of case-control or cohort design studies;(2)studies investigating the association between ANP polymorphism and essential hypertension;(3)full-text articles; and(4)hypertension was defined as at least three consecutive systolic blood pressure (SBP) measurements ≥ 140 mmHg or diastolic blood pressure (DBP) measurement ≥ 90 mmHg, or receiving antihypertensive pharmacotherapy treatment for at least 1 year; controls were healthy individuals in the same period.

2.3. Exclusion Criteria {#sec2dot3-ijerph-13-00458}
-----------------------

Studies that did not meet the following criteria were excluded: (1)duplicated studies;(2)reviews and literature without detailed genotype data;(3)studies with no controls;(4)unpublished articles, abstracts and comments;(5)subjects in the study were not human; and(6)SBP \< 140 mmHg or DBP \< 90 mmHg in cases or secondary hypertension or other serious cardiovascular disease of cases were excluded.

2.4. Data Extraction {#sec2dot4-ijerph-13-00458}
--------------------

The following data were independently extracted by two reviewers, and disagreements between the two reviews were resolved through discussion until the reviewers reached a consensus. The data extraction included: the first author's name, publication year, country, ethnicity, the number of cases and controls the sources of the subjects, genotyping methods, quality score, genotype distribution and allele frequency in cases and controls, and the Hardy-Weinberg equilibrium (HWE, *p* \< 0.05 was considered a significant difference from HWE).

2.5. Quality Assessment of the Included Studies {#sec2dot5-ijerph-13-00458}
-----------------------------------------------

The quality of the included studies was independently assessed by two reviewers, and disagreements between the two reviews were resolved through discussion until the reviewers reached a consensus. The quality of the included studies was evaluated using the Newcastle--Ottawa quality assessment scale \[[@B19-ijerph-13-00458]\]. The scale includes a total of three categories and eight entries. The number of stars represent the quality of studies. The highest quality research can be granted ten stars. Studies with six stars or higher than six stars were considered high quality.

2.6. Statistical Analysis {#sec2dot6-ijerph-13-00458}
-------------------------

The STATA 12.0 software (Stata, College Station, TX, USA) was chosen as the statistical analysis software for data management. To evaluate the associations between the ANP T2238C, G1837A and T1766C polymorphisms and the risk of EH, odds ratios (ORs) and 95% confidence intervals (95%CI) were calculated using five models, including an additive model (C *vs.* T), co-dominant model (TC *vs.* TT; CC *vs.* TT), dominant model ((CC + TC) *vs.* TT) and recessive model (CC *vs.* (TT + TC)) of the T2238C polymorphism and T1766C polymorphism. Pooled OR and 95%CI were also calculated under five genetic models including an additive model (A *vs.* G), co-dominant model (GA *vs.* GG; AA *vs.* GG), dominant model ((AA + GA) *vs.* GG) and recessive model (AA *vs.* (GG + GA)) of the G1837A polymorphism. *p* values and *I*^2^ were calculated using the Q-test. The *I*^2^ = \[100% × (Q − df/Q)\] test for heterogeneity between the results of different studies was conducted. The fixed effects model was used if *p* \> 0.10 and *I*^2^ \< 50%; the pooled OR and corresponding 95%CI were calculated using the Mantel-Haenszel method. Otherwise, a random effects model using the DerSimonian-Laird method was conducted to evaluate the pooled OR value. Begg's test and Egger's test were applied to evaluate the publication bias. *p* \< 0.1 indicated that there was significant publication bias, and a relevant funnel plot was drawn.

3. Results {#sec3-ijerph-13-00458}
==========

3.1. Characteristics of the Data Included in the Meta-Analysis {#sec3dot1-ijerph-13-00458}
--------------------------------------------------------------

According to the inclusion and exclusion, a total of 25 studies including 5520 cases and 5210 controls were available for this meta-analysis. The specific flow chart is shown in [Figure 1](#ijerph-13-00458-f001){ref-type="fig"}. The basic characteristics of the studies included are presented in [Table 1](#ijerph-13-00458-t001){ref-type="table"} and [Table 2](#ijerph-13-00458-t002){ref-type="table"}. The HWE test was also conducted to identify the genotype distribution of the controls in all of the studies. Three SNPs were analyzed, including T2238C, G1837A and T1766C, in 25 studies. Among the studies included in this meta-analysis, 15 articles explored the relationship between hypertension and T2238C polymorphism, six articles were about G1837A polymorphism and four articles were about T1766C polymorphism. Stratification occurred according to the source of subjects; two design methods were conducted including (P-B) population-based and (H-B) hospital-based; according to the ethnicity of the subjects, three races were considered, including Asian, White and Black. The four genotyping methods included PCR, polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP), gene chips and Q-PCR.

3.2. Meta-Analysis {#sec3dot2-ijerph-13-00458}
------------------

The results of the heterogeneity test of the total population of the association between T2238C polymorphisms and EH were as follows: C *vs.* T: *p*\* = 0.19, *I*^2^ = 23.6%; TC *vs.* TT: *p*\* = 0.053, *I*^2^ = 41.4%; CC *vs.* TT: *p*\* = 0.46, *I*^2^ = 0.0%; (CC + TC) *vs.* TT: *p*\* = 0.066, *I*^2^ = 39.2%; CC *vs.* (TT + TC): *p*\* = 0.18, *I*^2^ = 27.7% (*p*\*: *p* value of heterogeneity). The results of the test for heterogeneity of the overall population of G1837A polymorphisms and EH were as follows: A *vs.* G: *p*\* = 0.051, *I*^2^ = 54.7%; GA *vs.* GG: *p*\* = 0.005, *I*^2^ = 70.1%; AA *vs.* GG: *p*\* = 0.48, *I*^2^ = 0.0%; (AA + GA) *vs.* GG: *p*\* = 0.009, *I*^2^ = 67.5%; AA *vs.* (GG + GA): *p*\* = 0.53, *I*^2^ = 0.0% (*p*\*: *p* value of heterogeneity). In the overall population, if the test level α = 0.10, in the T2238C polymorphism analysis, except for the co-dominant model (TC *vs.* TT) and dominant model ((CC + TC) *vs.* TT), the other three models all met the level *p* \> 0.10 and *I*^2^ \< 50%; a random effects model was used in the co-dominant model (TC *vs.* TT) and dominant model ((CC + TC) *vs.* TT), and a fixed effects model was conducted in the other three genetic models. The forest plots of five genetic models of the total population between T2238C polymorphism and EH are presented in [Figure 2](#ijerph-13-00458-f002){ref-type="fig"}, [Figure 3](#ijerph-13-00458-f003){ref-type="fig"}, [Figure 4](#ijerph-13-00458-f004){ref-type="fig"}, [Figure 5](#ijerph-13-00458-f005){ref-type="fig"} and [Figure 6](#ijerph-13-00458-f006){ref-type="fig"}; the P value of significance test(s) of OR = 1 is shown in [Table 3](#ijerph-13-00458-t003){ref-type="table"}. Overall, no statistically significant associations between T2238C polymorphisms and EH were found in five models of the total population. The results of meta-analysis of the G1837A polymorphism and EH are shown in [Table 4](#ijerph-13-00458-t004){ref-type="table"}; five genetic models of the overall population were also conducted. The results of meta-analysis of the T1766C polymorphism and EH are presented in [Table 5](#ijerph-13-00458-t005){ref-type="table"}.

3.3. Sensitivity Analysis {#sec3dot3-ijerph-13-00458}
-------------------------

A sensitivity analysis was performed on three gene loci to evaluate the influence of each individual study on the pooled OR. The sensitivity analysis of the T2238C polymorphism showed that none of the fifteen studies included in this meta-analysis dramatically influenced the combined results under all of the five genetic models. The sensitivity analysis of the G1837A polymorphism suggested that Rutledge \[[@B30-ijerph-13-00458]\] significantly influenced the combined results under all of the five genetic models; the tests for heterogeneity changed significantly if the study of Rutledge was removed. The results indicated that the source of heterogeneity may be caused by ethnicity, as shown in [Table 4](#ijerph-13-00458-t004){ref-type="table"} and [Table 6](#ijerph-13-00458-t006){ref-type="table"}.

The forest plot of sensitivity analysis is presented in [Figure 7](#ijerph-13-00458-f007){ref-type="fig"}. Because the study of Rutledge \[[@B30-ijerph-13-00458]\] met the inclusion criteria, stricter interpretation needs to be conducted. Through the sensitivity analysis of T1766C polymorphism, the results become statistically significant under the genetic models of (TC *vs.* TT) and ((CC + TC) *vs.* TT) after excluding the study of Benedicta \[[@B35-ijerph-13-00458]\]. The results are shown in [Table 5](#ijerph-13-00458-t005){ref-type="table"} and [Table 7](#ijerph-13-00458-t007){ref-type="table"}, and the forest plot of sensitivity analysis is presented in [Figure 8](#ijerph-13-00458-f008){ref-type="fig"}. The results of this study need to be interpreted carefully because this study met the inclusion criteria.

3.4. Subgroup Analysis {#sec3dot4-ijerph-13-00458}
----------------------

According to the ethnicity of subjects, genotyping methods, and the source of controls, a stratified analysis was performed on the T2238C polymorphism to explore the sources of heterogeneity as follows. In the test for heterogeneity of ethnic subgroups in the T2238C additive model, the P value of heterogeneity in Asian and White subgroups was 0.472 and 0.015, respectively, and the *I*^2^ in Asian and White subgroups was 0.0% and 76.1%, respectively, so a random effects model was conducted to estimate the summary OR and corresponding 95%CI. Ethnic subgroup analysis of the association between T2238C polymorphisms and EH of the other four models is shown in [Figure 9](#ijerph-13-00458-f009){ref-type="fig"}, [Figure 10](#ijerph-13-00458-f010){ref-type="fig"}, [Figure 11](#ijerph-13-00458-f011){ref-type="fig"}, [Figure 12](#ijerph-13-00458-f012){ref-type="fig"} and [Figure 13](#ijerph-13-00458-f013){ref-type="fig"} and [Table 3](#ijerph-13-00458-t003){ref-type="table"}. According to the test for heterogeneity of the subgroups analysis in the sources of controls of the T2238C additive model (C *vs.* T), the *p* value of heterogeneity in HB and PB was 0.289 and 0.264, respectively, and the *I*^2^ in HB and PB was 19.7% and 19.5%, respectively, so a fixed effects model was conducted to estimate the summary OR and corresponding 95%CI. The subgroup analysis of the sources of controls of the association between T2238C polymorphisms and EH of the other four models are shown in [Figure 14](#ijerph-13-00458-f014){ref-type="fig"}, [Figure 15](#ijerph-13-00458-f015){ref-type="fig"}, [Figure 16](#ijerph-13-00458-f016){ref-type="fig"}, [Figure 17](#ijerph-13-00458-f017){ref-type="fig"} and [Figure 18](#ijerph-13-00458-f018){ref-type="fig"} and [Table 3](#ijerph-13-00458-t003){ref-type="table"}. In the subgroup analysis of genotyping methods of the association between T2238C polymorphisms and EH, the fixed effects model was used in the co-dominant model-2 (CC *vs.* TT), and a random effects model was conducted in the other four models. The forest plots of the five models and the results of the meta-analysis are shown in [Figure 19](#ijerph-13-00458-f019){ref-type="fig"}, [Figure 20](#ijerph-13-00458-f020){ref-type="fig"}, [Figure 21](#ijerph-13-00458-f021){ref-type="fig"}, [Figure 22](#ijerph-13-00458-f022){ref-type="fig"} and [Figure 23](#ijerph-13-00458-f023){ref-type="fig"} and [Table 3](#ijerph-13-00458-t003){ref-type="table"}.

3.5. Publication Bias {#sec3dot5-ijerph-13-00458}
---------------------

An evaluation of publication bias of T2238C polymorphism was conducted for the 15 articles included in this meta-analysis. No obvious publication bias was found in the meta-analysis under the five genetic models. Both Begg's test and Egger's test were conducted. The *p* values of Begg's and Egger's test under the five genetic models all satisfied *p* \> 0.1, the results indicated that there was no significant publication bias, and Begg's test funnel plot was drawn, as seen in [Figure 24](#ijerph-13-00458-f024){ref-type="fig"}.

4. Discussion {#sec4-ijerph-13-00458}
=============

Many gene loci in human ANP gene associated with essential hypertension have been found, including the T2238C, G1837A, T1766C, C664G, C1364A, G658A and G664A gene polymorphisms. Robert explored the relationship between the ANF gene and essential hypertension in terms of causation. However, the results provided no evidence for the involvement of the ANF gene polymorphism with EH \[[@B37-ijerph-13-00458]\]. Rutledge investigated gene polymorphisms within the atrial natriuretic peptide of African Americans at intron two and exon three in essential hypertension and found that the *Hpa*II polymorphism was associated with hypertension \[[@B30-ijerph-13-00458]\]. Cheung discovered that the allele distribution H1 and H2 of the *Hpa*II polymorphism of the atrial natriuretic peptide gene in hypertensive patients and normotensive controls were 0.12 and 0.88, and 0.11 and 0.89, respectively. The results indicated no obvious association with hypertension in this population \[[@B32-ijerph-13-00458]\]. Zorc-Pleskovic analyzed the T2238C *Sca*I gene polymorphism of the ANF gene in a group of children with EAH, and the results also failed to find an association between the T2238C gene polymorphism and EH in children \[[@B27-ijerph-13-00458]\]. In our study, no obvious association was found in the gene locus of T2238C, G1837A and EH.

More epidemiological studies investigating the correlation between the atrial natriuretic peptide (ANP) genetic polymorphism and the risk of essential hypertension worldwide have emerged. However, these studies have reported inconsistent, even contradictory results. Considering the limited sample size of individual studies and the great clinical heterogeneity, meta-analysis can provide a more reliable estimation using quantitative synthesis methods. A meta-analysis can collect all the relevant studies published or unpublished systematically and comprehensively. The aim of this meta-analysis is to make a more reliable estimation of the possible relationship between the atrial natriuretic peptide genetic polymorphism and the risk of essential hypertension. A few meta-analyses have been conducted to explore the associations between the ANP gene polymorphisms and the risk of EH. However, this meta-analysis is the first to collect relevant articles published on three common gene loci of the ANP gene polymorphism and EH. Although Niu \[[@B38-ijerph-13-00458]\] conducted a meta-analysis of the relationship between a natriuretic peptide precursor, the T2238C polymorphism and hypertension, the articles included were limited and the gene locus only included the T2238C polymorphism. In Niu \[[@B38-ijerph-13-00458]\], only seven studies were included; the results indicated that the 2238C allele decreased risk of developing hypertension, a results that is inconsistent with the results of this meta-analysis.

A sensitivity analysis was also conducted in the present study on three gene loci to evaluate the influence of each individual study on the pooled OR. The sensitivity analysis of the T2238C polymorphism showed that none of the fifteen studies included in this meta-analysis substantially influenced the combined results under all five genetic models. The forest plot of sensitivity analysis of the overall population of the T2238C polymorphism is shown in [Figure 25](#ijerph-13-00458-f025){ref-type="fig"}. The sensitivity analysis of the G1837A polymorphism suggested that Rutledge \[[@B30-ijerph-13-00458]\] significantly influenced the combined results under all five genetic models; the tests for heterogeneity changed significantly if the study of Rutledge \[[@B30-ijerph-13-00458]\] was removed. The ethnicity of Rutledge \[[@B30-ijerph-13-00458]\] was Black, and the remaining five studies were all Asians, which indicated that the source of heterogeneity may be caused by ethnicity. Through sensitivity analysis of the T1766C polymorphism, the results become statistically significant under the genetic models of (TC *vs.* TT) and ((CC + TC) *vs.* TT) after excluding the study of Benedicta \[[@B35-ijerph-13-00458]\]. Therefore, the results of this study need to be interpreted carefully.

In the meta-analysis of Niu \[[@B38-ijerph-13-00458]\], the subgroup analysis of the T2238C polymorphism by study design presented opposite results for the HB and PB groups. However, in the subgroup analysis of this meta-analysis of the ANP T2238C polymorphism by the ethnicity of subjects, no obvious association was found in Asians, Whites and Blacks under the five genetic models in the overall population. Moreover, in the subgroup analysis of the ANP T2238C polymorphism by genotyping methods, no significant difference was found in PCR, PCR-RFLP, gene chips and Q-PCR under the five genetic models. Similarly, in the subgroup analysis of the ANP T2238C polymorphism by the source of controls, there was no apparent association between the T2238C polymorphism and EH in the (PB) population-based and (HB) hospital-based controls under the five genetic models. The forest plots in the subgroup analysis of the ANP T2238C polymorphism by the ethnicity of subjects, genotyping methods and the source of controls under the five genetic models were presented in [Figure 9](#ijerph-13-00458-f009){ref-type="fig"}, [Figure 10](#ijerph-13-00458-f010){ref-type="fig"}, [Figure 11](#ijerph-13-00458-f011){ref-type="fig"}, [Figure 12](#ijerph-13-00458-f012){ref-type="fig"}, [Figure 13](#ijerph-13-00458-f013){ref-type="fig"}, [Figure 14](#ijerph-13-00458-f014){ref-type="fig"}, [Figure 15](#ijerph-13-00458-f015){ref-type="fig"}, [Figure 16](#ijerph-13-00458-f016){ref-type="fig"}, [Figure 17](#ijerph-13-00458-f017){ref-type="fig"}, [Figure 18](#ijerph-13-00458-f018){ref-type="fig"}, [Figure 19](#ijerph-13-00458-f019){ref-type="fig"}, [Figure 20](#ijerph-13-00458-f020){ref-type="fig"}, [Figure 21](#ijerph-13-00458-f021){ref-type="fig"}, [Figure 22](#ijerph-13-00458-f022){ref-type="fig"} and [Figure 23](#ijerph-13-00458-f023){ref-type="fig"}.

5. Conclusions {#sec5-ijerph-13-00458}
==============

In conclusion, this meta-analysis indicates that the ANPT2238C, G1837A gene polymorphism may have no relationship with EH; conversely, the ANP T1766C gene polymorphism is likely to be associated with EH. Considering the limited articles included in this meta-analysis of T1766C polymorphism, more articles are needed for future studies. According to the sensitivity analysis and publication bias evaluation, no obvious publication bias was found, which indicates that the conclusion of this article is basically reliable and stable.
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###### 

Characteristics of studies included in the meta-analysis.

  Author                                           Year   Locus    Source   Country   Ethnicity   Number             Genotyping Methods   Quality Score                
  ------------------------------------------------ ------ -------- -------- --------- ----------- ------------------ -------------------- --------------- ------------ ---
  Hu *et al.* \[[@B17-ijerph-13-00458]\]           2014            H-B      H-B       China       Asian (Han)        100                  97              Gene chips   6
  Soualmia *et al.* \[[@B14-ijerph-13-00458]\]     2014            H-B      P-B       Tunisia     White (Tunisian)   384                  453             PCR-RFLP     7
  Liang *et al.* \[[@B20-ijerph-13-00458]\]        2011            P-B      P-B       China       Asian (Han)        205                  260             PCR-RFLP     6
  Liang *et al.* \[[@B20-ijerph-13-00458]\]        2011            P-B      P-B       China       Asian (Kazakh)     218                  232             PCR-RFLP     6
  Xiong *et al.* \[[@B21-ijerph-13-00458]\]        2010            H-B      H-B       China       Asian (Han)        81                   120             Gene chips   5
  Tian and Cheng \[[@B22-ijerph-13-00458]\]        2010            H-B      P-B       China       Asian (Han)        976                  976             Q-PCR        6
  Wang and Mao \[[@B23-ijerph-13-00458]\]          2009            H-B      H-B       China       Asian (Han)        238                  184             Gene chips   4
  Li \[[@B24-ijerph-13-00458]\]                    2007            P-B      P-B       China       Asian (Yi)         99                   134             PCR          5
  Li \[[@B24-ijerph-13-00458]\]                    2007            P-B      P-B       China       Asian (Hani)       172                  133             PCR          5
  Zhang YM \[[@B25-ijerph-13-00458]\]              2006            P-B      P-B       China       Asian (Kazakh)     314                  229             PCR-RFLP     6
  Li *et.al.* \[[@B26-ijerph-13-00458]\]           2005            P-B      P-B       China       Asian (Kazakh)     313                  205             PCR-RFLP     6
  Zorc *et.al.* \[[@B27-ijerph-13-00458]\]         2004            H-B      H-B       Slovenia    Caucasian          58                   57              PCR          6
  Nannipieri *et.al.* \[[@B28-ijerph-13-00458]\]   2001            P-B      P-B       Europeans   White              121                  105             PCR-RFLP     6
  Rahmutula *et.al.* \[[@B29-ijerph-13-00458]\]    2001            H-B      H-B       Japan       Asian              233                  213             PCR          3
  Rutledge *et.al.* \[[@B30-ijerph-13-00458]\]     1995            H-B      P-B       American    Black              60                   44              PCR          6
                                                          G1837A   case     control                                  case                 control                      
  Li \[[@B24-ijerph-13-00458]\]                    2007            P-B      P-B       China       Asian (Yi)         99                   134             PCR          5
  Li \[[@B24-ijerph-13-00458]\]                    2007            P-B      P-B       China       Asian (Hani)       172                  133             PCR          5
  Zhang *et.al.* \[[@B31-ijerph-13-00458]\]        2005            P-B      P-B       China       Asian (Kazakh)     287                  190             PCR-RFLP     5
  Rahmutula *et.al.* \[[@B29-ijerph-13-00458]\]    2001            H-B      H-B       Japan       Asian              233                  213             PCR          3
  Bernard *et.al.* \[[@B32-ijerph-13-00458]\]      1999            H-B      P-B       China       Asian              108                  109             PCR          6
  Rutledge *et.al.* \[[@B30-ijerph-13-00458]\]     1995            H-B      P-B       American    Black              60                   44              PCR          6
                                                          T1766C   case     control                                  case                 control                      
  He \[[@B33-ijerph-13-00458]\]                    2007            P-B      P-B       China       Asian (Kazakh)     199                  198             PCR-RFLP     5
  He *et.al.* \[[@B34-ijerph-13-00458]\]           2007            P-B      P-B       China       Asian (Kazakh)     246                  244             PCR-RFLP     5
  Benedicta *et.al.* \[[@B35-ijerph-13-00458]\]    2002            H-B      P-B       African     Black              289                  278             PCR-RFLP     6
  Kato *et.al.* \[[@B36-ijerph-13-00458]\]         2000            H-B      H-B       Japan       Asian              255                  225             PCR          5

P-B: population-based; H-B: hospital-based.

ijerph-13-00458-t002_Table 2

###### 

The allele gene and genotype frequency of ANP polymorphisms in the meta-analysis.

  Author                                           Year   Locus    Allele Number   Gene Number   HWE                                              
  ------------------------------------------------ ------ -------- --------------- ------------- ------ ----- ----- ----- ----- ----- ----- ----- -----
  Hu *et.al.* \[[@B17-ijerph-13-00458]\]           2014            197             3             190    4     97    3     0     93    4     0     YES
  Soualmia *et.al.* \[[@B14-ijerph-13-00458]\]     2014            372             396           448    458   27    318   39    50    348   55    NO
  Liang *et.al.* \[[@B20-ijerph-13-00458]\]        2011            246             164           320    200   50    146   9     62    196   2     YES
  Liang *et.al.* \[[@B20-ijerph-13-00458]\]        2011            322             114           329    135   108   106   4     103   123   6     YES
  Xiong *et.al.* \[[@B21-ijerph-13-00458]\]        2010            146             16            213    27    70    6     5     103   7     10    YES
  Tian and Cheng \[[@B22-ijerph-13-00458]\]        2010            1934            18            1936   16    960   14    2     962   12    2     YES
  Wang and Mao \[[@B23-ijerph-13-00458]\]          2009            458             18            363    5     220   18    0     179   5     0     YES
  Li \[[@B24-ijerph-13-00458]\]                    2007            195             3             266    2     96    3     0     132   2     0     YES
  Li \[[@B24-ijerph-13-00458]\]                    2007            338             6             260    6     166   6     0     127   6     0     YES
  Zhang YM \[[@B25-ijerph-13-00458]\]              2006            584             44            433    25    277   30    7     206   21    2     YES
  Li *et.al.* \[[@B26-ijerph-13-00458]\]           2005            581             45            390    20    273   35    5     187   16    2     YES
  Zorc *et.al.* \[[@B27-ijerph-13-00458]\]         2004            30              86            41     73    2     26    30    4     33    20    YES
  Nannipieri *et.al.* \[[@B28-ijerph-13-00458]\]   2001            216             26            171    39    95    26    0     67    37    1     YES
  Rahmutula *et.al.* \[[@B29-ijerph-13-00458]\]    2001            11              455           13     413   0     11    222   0     13    200   YES
  Rutledge *et.al.* \[[@B30-ijerph-13-00458]\]     1995            70              50            54     34    17    36    7     19    16    9     YES
                                                          G1837A   G               A             G      A     GG    GA    AA    GG    GA    AA    
  Li \[[@B24-ijerph-13-00458]\]                    2007            178             20            245    23    79    20    0     113   19    2     YES
  Li \[[@B24-ijerph-13-00458]\]                    2007            296             48            233    33    127   42    3     101   31    1     YES
  Zhang *et.al.* \[[@B31-ijerph-13-00458]\]        2005            514             60            346    34    228   58    1     158   30    2     YES
  Rahmutula *et.al.* \[[@B29-ijerph-13-00458]\]    2001            42              424           47     379   3     36    194   1     45    167   YES
  Bernard *et.al.* \[[@B32-ijerph-13-00458]\]      1999            191             25            195    23    86    19    3     87    21    1     YES
  Rutledge *et.al.* \[[@B30-ijerph-13-00458]\]     1995            90              30            85     3     30    30    0     41    3     0     YES
                                                          T1766C   T               C             T      C     TT    TC    CC    TT    TC    CC    
  He \[[@B33-ijerph-13-00458]\]                    2007            304             94            291    105   108   88    3     95    101   2     YES
  He *et.al.* \[[@B34-ijerph-13-00458]\]           2007            290             202           267    221   49    192   5     29    209   6     YES
  Benedicta *et.al.* \[[@B35-ijerph-13-00458]\]    2002            333             245           311    245   87    159   43    85    141   52    YES
  Kato *et.al.* \[[@B36-ijerph-13-00458]\]         2000            506             4             440    10    251   4     0     215   10    0     YES
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###### 

Meta-analysis of T2238C polymorphism and EH.

  Stratification Factors   No.   Additive Model (C *vs.* T)   *p*     Co-Dominant Model-1 (TC *vs.* TT)   *p*     Co-Dominant Model-2 (CC *vs.* TT)   *p*     Dominant Model (CC + TC) *vs.* TT   *p*    Recessive Model CC *vs.* (TT + TC)   *p*
  ------------------------ ----- ---------------------------- ------- ----------------------------------- ------- ----------------------------------- ------- ----------------------------------- ------ ------------------------------------ ------
  Overall                  15    1.1(0.94--1.2)               0.38    1.1(0.88--1.5)                      0.32    1.3(0.90--1.9)                      0.16    1.1(0.88--1.4)                      0.35   1.1(0.83--1.4)                       0.55
  Ethnicity                                                                                                                                                                                                                                   
  Asian                    11    1.1(0.92--1.3)               0.38    1.0(0.84--1.3)                      0.75    1.4(0.81--2.4)                      0.23    1.1(0.86--1.3)                      0.62   1.3(0.81--2.2)                       0.26
  White                    3     0.96(0.58--1.6)              0.89    1.0(0.38--2.7)                      0.96    1.3 (0.76--2.4)                     0.32    1.1(0.39--2.9)                      0.91   1.1(0.51--2.4)                       0.80
  Black                    1     1.1(0.65--2.0)               0.66    2.5(1.0--6.1)                       0.040   0.87(0.27--2.8)                     0.82    1.9(0.85--4.4)                      0.12   0.51(0.18--1.5)                      0.23
  Source of controls                                                                                                                                                                                                                          
  HB                       5     1.4(0.97--1.9)               0.073   1.6(0.87--3.1)                      0.13    1.1(0.45--2.7)                      0.83    1.4(0.73--2.8)                      0.30   1.4(0.85--2.3)                       0.19
  PB                       10    1.0(0.90--1.1)               0.77    1.1(0.82--1.4)                      0.58    1.4(0.90--2.1)                      0.15    1.1(0.83--1.4)                      0.57   0.97(0.70--1.4)                      0.86
  Genotyping methods                                                                                                                                                                                                                          
  Gene chips               3     1.2(0.53--2.9)               0.62    1.6(0.72--3.5)                      0.25    0.74(0.24--2.2)                     0.59    1.3(0.58--3.1)                      0.50   0.72(0.24--2.2)                      0.57
  PCR-RFLP                 6     1.0(0.82--1.2)               1.0     1.0(0.72--1.4)                      0.99    1.5(0.93--2.3)                      0.096   1.0(0.73--1.4)                      0.91   1.3(0.64--2.6)                       0.48
  Q-PCR                    1     1.1(0.57--2.2)               0.73    1.2(0.54--2.5)                      0.69    1.0(0.14--7.1)                      1.0     1.1(0.56--2.4)                      0.71   1.0(0.14--7.1)                       1.0
  PCR                      5     1.3(0.93--1.8)               0.13    1.7(0.90--3.1)                      0.10    1.3(0.49--3.4)                      0.61    1.5(0.85--2.8)                      0.15   1.2(0.58--2.5)                       0.62

**^a^**: pooled OR and relevant 95%CI; *p*: *p* value of significance test(s) of OR = 1.
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###### 

Meta-analysis of G1837A polymorphism and EH.

  Gene Type                  Genetic Model         OR ^a^   95%CI       *p*     *I*^2^   *p*\*   Model
  -------------------------- --------------------- -------- ----------- ------- -------- ------- -------
  Overall                                                                                        
  A *vs.* G                  additive model        1.3      0.96--1.9   0.090   54.7%    0.051   RE
  GA *vs.* GG                co-dominant model-1   1.5      0.83--2.6   0.19    70.1%    0.005   RE
  AA *vs.* GG                co-dominant model-2   0.87     0.34--2.3   0.78    0.0%     0.48    FE
  (AA + GA) *vs.* GG         dominant model        1.5      0.86--2.5   0.17    67.5%    0.009   RE
  AA *vs.* (GG + GA)         recessive model       1.3      0.85--2.0   0.22    0.0%     0.53    FE
  Work of Rutledge removed                                                                       
  A *vs.* G                  additive model        1.2      0.95--1.5   0.14    0.0%     1.0     FE
  GA *vs.* GG                co-dominant model-1   1.2      0.88--1.6   0.29    0.0%     0.56    FE
  AA *vs.* GG                co-dominant model-2   0.87     0.34--2.3   0.78    0.0%     0.48    FE
  (AA + GA) *vs.* GG         dominant model        1.2      0.88--1.5   0.28    0.0%     0.82    FE
  AA *vs.* (GG + GA)         recessive model       1.3      0.85--2.0   0.22    0.0%     0.53    FE

**^a^**: pooled OR and relevant 95%CI; *p*: *p* value of significance test(s) of OR = 1; ***p*\***: *p* value of heterogeneity; FE: fixed effect model; RE: random effect model.

ijerph-13-00458-t005_Table 5

###### 

Meta-analysis of T1766C polymorphism and EH.

  Gene Type                   Genetic Model         OR ^a^   95%CI        *p*     *I*^2^   *p*\*   Model
  --------------------------- --------------------- -------- ------------ ------- -------- ------- -------
  Overall                                                                                          
  C *vs.* T                   additive model        0.87     0.75--1.0    0.063   0.0%     0.42    FE
  TC *vs.* TT                 co-dominant model-1   0.73     0.49--1.1    0.12    58.0%    0.068   RE
  CC *vs.* TT                 co-dominant model-2   0.78     0.50--1.2    0.29    0.0%     0.66    FE
  (CC + TC) *vs.* TT          dominant model        0.73     0.51--1.0    0.084   51.1%    0.11    RE
  CC *vs.* (TT + TC)          recessive model       0.79     0.53--1.2    0.26    0.0%     0.77    FE
  Work of Benedicta removed                                                                        
  C *vs.* T                   additive model        0.82     0.68--1.0    0.052   8.4%     0.34    FE
  TC *vs.* TT                 co-dominant model-1   0.64     0.47--0.86   0.003   12.7%    0.32    FE
  CC *vs.* TT                 co-dominant model-2   0.69     0.25--1.9    0.48    0.0%     0.38    FE
  (CC + TC) *vs.* TT          dominant model        0.64     0.48--0.87   0.004   18.1%    0.30    FE
  CC *vs.* (TT + TC)          recessive model       0.99     0.37--2.7    0.99    0.0%     0.59    FE

**^a^**: pooled OR and relevant 95%CI; *p*: *p* value of significance test(s) of OR = 1; ***p*\***: *p* value of heterogeneity; FE: fixed effect model; RE: random effect model.
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###### 

Sensitivity analysis of G1837A polymorphism and EH (GA *vs.* GG).

  Study Omitted                                          Estimate   95%Confidence Interval
  ------------------------------------------------------ ---------- ------------------------
  Li (2007) \[[@B24-ijerph-13-00458]\]                   1.4        1.0--1.9
  Li (2007) \[[@B24-ijerph-13-00458]\]                   1.5        1.1--2.1
  Zhang *et.al.* (2005) \[[@B31-ijerph-13-00458]\]       1.4        1.0--2.0
  Rahmutula *et.al.* (2001) \[[@B29-ijerph-13-00458]\]   1.4        1.1--1.9
  Bernard *et.al.* (1999) \[[@B32-ijerph-13-00458]\]     1.5        1.1--2.0
  Rutledge *et.al.* (1995) \[[@B30-ijerph-13-00458]\]    1.2        0.88--1.6
  Combined                                               1.4        1.1--1.8
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###### 

Sensitivity analysis of T1766C polymorphism and EH (TC *vs.* TT).

  Study Omitted                                         Estimate   95%Confidence Interval
  ----------------------------------------------------- ---------- ------------------------
  He (2007) \[[@B33-ijerph-13-00458]\]                  0.80       0.60--1.1
  He *et.al.*(2007) \[[@B34-ijerph-13-00458]\]          0.88       0.67--1.1
  Benedicta *et.al.*(2002) \[[@B35-ijerph-13-00458]\]   0.64       0.47--0.86
  Kato *et.al.*(2000) \[[@B36-ijerph-13-00458]\]        0.82       0.65--1.0
  Combined                                              0.79       0.62--0.99
